Trials / Completed
CompletedNCT06652035
Possible Pharmacological Effect of Quercetin in the Management of Hyperuricemia - Results From Real-life Clinical Studies
Possible Pharmacological Effect of Quercetin in the Management of Hyperuricemia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 161 (actual)
- Sponsor
- Liaquat University of Medical & Health Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Quercetin, a natural flavonoid found in various fruits and vegetables, has gained attention for its potential role in managing hyperuricemia. Emerging evidence suggests that quercetin may reduce plasma uric acid levels by inhibiting xanthine oxidase, an enzyme responsible for uric acid production. Additionally, its anti-inflammatory and antioxidant properties could help mitigate the oxidative stress and inflammation associated with hyperuricemia. As a result, quercetin supplementation offers a promising avenue for therapeutic intervention in conditions like gout and other uric acid-related disorders.
Detailed description
In the present retrospective cross-sectional observational study, the investigators assessed the potential pharmacological effect of supplemental quercetin on the plasma uric acid levels of health adults. These participants visited nutritional clinics in Italy during the Coronavirus disease (COVID-19) pandemic for general health check-up in real-life to enhance their immune system with supplements aimed at providing additional protection against COVID-19 infection. The supplements, either quercetin or probiotic Streptococcus salivarius K12 (BLIS K12), were advised randomly to the participants for 90 days, tailored to individual needs and in the absence of any pre-defined criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Quevir® (Quercetin Phytosome®) | 500 mg Quevir® (Quercetin Phytosome®) tablet |
| DIETARY_SUPPLEMENT | Bactoblis® | Probiotic Streptococcus Salivarius K12 (ATCC BAA-1024) |
Timeline
- Start date
- 2021-09-01
- Primary completion
- 2022-12-31
- Completion
- 2023-06-15
- First posted
- 2024-10-22
- Last updated
- 2024-10-29
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06652035. Inclusion in this directory is not an endorsement.